오믹스 기반 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 시험 설계별, 적응증별, 지역별, 부문별 예측(2025-2030년)

Omics-Based Clinical Trials Market Growth & Trends:

The global omics-based clinical trials market size is anticipated to reach USD 51.77 billion by 2030, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 8.02% from 2025 to 2030. Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix - omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.

The outbreak of COVID-19 has caused havoc and has disrupted almost every sector of industry. Initially, the outbreak has negatively impacted the ecosystem of clinical trials and affected many ongoing studies for numerous indications. However, in the second half of 2020, researchers started developing innovative therapeutics and vaccines against COVID-19, which has supported the market recovery and growth, and continuance of business by CROs. There has been an increase in the clinical trials activity with oncology trials attaining historically high levels. The extensive research for understanding the COVID-19 infection has turned the attention to the application of omics-based studies.

For instance, in June 2021, a group of researchers at University Hospital Tuebingen initiated a clinical trial on comparative genetic and immune response analysis of different COVID-19 vaccine candidates using a multi-omics approach. The growing application of spatial OMICS, for the identification of biomarkers, is a major factor boosting the growth of the market. To study the efficacy and toxicity of the drug, spatial OMICS play a major role and have simplified drug discovery and development. Biomarker identification along with the clinical application is widely used in drug development and discovery. Biomarkers are used to identify the pathway of the diseases and the progression and help to understand the cause.

The rising prevalence of chronic diseases such as cancer and cardiac disorders and the increasing demand for omics-based clinical trials in developing countries are boosting the market's growth. Cancer is one of the leading causes of death in the United States. In 2018 alone, there were an estimated 1,735,350 new diagnoses and 609,640 cancer-related deaths. Single-cell multi-OMIC analysis is a novel tool that is opening doors in cancer drug development and further advance the current treatment options. The market is also driven by a rising number of biologics, demand for advanced technologies, and the need for personalized medicines and orphan drugs. Additionally, growing biotechnology and the pharmaceutical industry have propelled the demand for non-invasive instruments, full applications for single-cell multi-omics technology, and conventional labs are bolstering future market growth.

Omics-Based Clinical Trials Market Report Highlights:

• The phase III segment dominated the market, accounting for 54.5% of the total revenue share in 2024. Clinical trial statistics indicate that market growth is driven by an increase in phase III trials, which typically involve a large number of participants.
• The interventional studies segment dominated the market in 2024 owing to its growing emphasis on personalized medicine by facilitating tailored interventions based on individual patient profiles derived from omics technologies.
• The oncology segment dominated the market in 2024 owing to increasing prevalence of cancer globally coupled with growing need for more effective treatment strategies.
• North America omics-based clinical trials market dominated the global industry and accounted for a 38.0% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Omics-Based Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Investment by Major Pharmaceutical Companies
    • 3.2.1.2. Shift Towards Personalized Medicine
    • 3.2.1.3. Growing Prevalence of Chronic Disorders
    • 3.2.1.4. Increasing Partnership and Collaboration
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rising Costs of Clinical Trials
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Omics-Based Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Omics-Based Clinical Trials Market; Phase Movement Analysis
• 4.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Omics-Based Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Omics-Based Clinical Trials Market; Study Design Movement Analysis
• 5.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
• 5.4. Interventional Studies
  • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Observational Studies
  • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Expanded Access Studies
  • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Omics-Based Clinical Trials Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Omics-Based Clinical Trials Market; Indication Movement Analysis
• 6.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 6.4. Autoimmune/inflammation
  • 6.4.1. Autoimmune/inflammation market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Pain management
  • 6.5.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. CNS conditions
  • 6.7.1. CNS conditions market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Obesity
  • 6.9.1. Obesity market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Cardiovascular
  • 6.10.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Omics-Based Clinical Trials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Parexel International (MA) Corporation
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Thermo Fisher Scientific Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Charles River Laboratories
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. ICON plc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. SGS Societe Generale de Surveillance SA
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Eli Lilly and Company
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Pfizer Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Laboratory Corporation of America
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Novo Nordisk A/S
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Rebus Biosystems, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives